EVIDENCE FOR A POLARIZED EFFLUX SYSTEM IN CACO-2 CELLS CAPABLE OF MODULATING CYCLOSPORINE-A TRANSPORT

被引:159
作者
AUGUSTIJNS, PF
BRADSHAW, TP
GAN, LSL
HENDREN, RW
THAKKER, DR
机构
[1] GLAXO INC,RES INST,DEPT DRUG METAB,RES TRIANGLE PK,NC 27709
[2] GLAXO INC,RES INST,DEPT OLIGOMER DEV,RES TRIANGLE PK,NC 27709
关键词
D O I
10.1006/bbrc.1993.2487
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The characteristics of cyclosporin A (CsA) transport across Caco-2 monolayers were investigated. CsA (0.25 - 5.0 μM) was transported in a time and concentration dependent manner. The total amount of apical (AP) to basolateral (BL) transport was non-linearly related to CsA concentration from 0.25 to 1 μM and was linear from about 1 to 5 μM. Average permeability coefficient (Papp) values obtained in the AP to BL direction showed CsA concentration (0.5 and 5.0 μM) dependence, whereas those of the reverse (BL to AP) process did not. Papp values for the AP to BL direction were also markedly lower. When the P-glycoprotein pump inhibitors, chlorpromazine and progesterone, were included in the transport medium we observed a significant increase in CsA (0.5 and 5.0 μM) transport from the AP to BL direction; transport was decreased in the reverse direction. This study suggests that CsA is transported across Caco-2 cells by passive diffusion, but that a polarized efflux system (presumably a P-glycoprotein pump) located at the apical membrane can attenuate the net AP to BL transport. © 1993 Academic Press, Inc.
引用
收藏
页码:360 / 365
页数:6
相关论文
共 19 条
[1]   EVIDENCE FOR A POLARIZED EFFLUX SYSTEM FOR PEPTIDES IN THE APICAL MEMBRANE OF CACO-2 CELLS [J].
BURTON, PS ;
CONRADI, RA ;
HILGERS, AR ;
HO, NFH .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1993, 190 (03) :760-766
[2]  
CHUNG YH, 1983, J PHARMACOBIO-DYNAM, V6, P829
[3]   EXPRESSION OF THE MULTIDRUG RESISTANCE GENE-PRODUCT (P-GLYCOPROTEIN) IN HUMAN NORMAL AND TUMOR-TISSUES [J].
CORDONCARDO, C ;
OBRIEN, JP ;
BOCCIA, J ;
CASALS, D ;
BERTINO, JR ;
MELAMED, MR .
JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY, 1990, 38 (09) :1277-1287
[4]   IDENTIFICATION OF SEVERAL CYCLOSPORINE BINDING-PROTEINS IN LYMPHOID AND NONLYMPHOID CELLS INVIVO [J].
FOXWELL, BMJ ;
WOERLY, G ;
HUSI, H ;
MACKIE, A ;
QUESNIAUX, VFJ ;
HIESTAND, PC ;
WENGER, RM ;
RYFFEL, B .
BIOCHIMICA ET BIOPHYSICA ACTA, 1992, 1138 (02) :115-121
[5]  
Herbert Mary F., 1992, Clinical Pharmacology and Therapeutics, V52, P453
[6]  
HUMPHREY MJ, 1986, NATO ADV RES WORKSHO, P139
[7]   DRUG ABSORPTION LIMITED BY P-GLYCOPROTEIN-MEDIATED SECRETORY DRUG TRANSPORT IN HUMAN INTESTINAL EPITHELIAL CACO-2 CELL-LAYERS [J].
HUNTER, J ;
HIRST, BH ;
SIMMONS, NL .
PHARMACEUTICAL RESEARCH, 1993, 10 (05) :743-749
[8]   UNUSUAL SOLUBILITY BEHAVIOR OF CYCLOSPORINE-A IN AQUEOUS-MEDIA [J].
ISMAILOS, G ;
REPPAS, C ;
DRESSMAN, JB ;
MACHERAS, P .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 1991, 43 (04) :287-289
[9]   CYCLOSPORINE METABOLISM BY P450IIIA IN RAT ENTEROCYTES - ANOTHER DETERMINANT OF ORAL BIOAVAILABILITY [J].
KOLARS, JC ;
STETSON, PL ;
RUSH, BD ;
RUWART, MJ ;
SCHMIEDLINREN, P ;
DUELL, EA ;
VOORHEES, JJ ;
WATKINS, PB .
TRANSPLANTATION, 1992, 53 (03) :596-602
[10]   FACTORS INFLUENCING THE PHARMACOKINETICS OF CYCLOSPORINE IN MAN [J].
LINDHOLM, A .
THERAPEUTIC DRUG MONITORING, 1991, 13 (06) :465-477